Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601910 | 0.86 | ALDH1A1 (0.54) | KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL329695 | 0.82 | PAOX (0.38) | USP2PAOXALDH1A1 | |
| SCHEMBL2561394 | 0.82 | EPHX1 (0.48) | KMT2A | |
| SCHEMBL2616667 | 0.81 | TDP1 (0.49) | KDM4ESMN1; SMN2CNR1ALDH1A1 | |
| SCHEMBL33525089 | 0.80 | CNR1 (0.46) | KMT2AKDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL4419366 | 0.80 | EPHX1 (0.47) | KMT2A | |
| SCHEMBL13529065 | 0.79 | ACHE (0.46) | USP2TP53SMN1; SMN2 | |
| SCHEMBL4362272 | 0.78 | EPHX1 (0.55) | KDM4E | |
| SCHEMBL17133248 | 0.77 | EPHX1 (0.41) | KMT2A | |
| SCHEMBL4355762 | 0.77 | EPHX1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511484-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | Promega Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119095959-A | Compounds, compositions and methods for isolating nucleic acids | 普罗美加公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20230382875-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | PROMEGA CORPORATION | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382875-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | POLRMT, POLN, NOP2 | KMT2A 2369/4885KDM4E 4054/4885HSD17B10 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.